Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Analyse IA de METACRINE INC
Cliquez sur l’une des analyses ci-dessous pour obtenir des informations instantanées de l’IA via finAgent